skip to main content

Fingolimod – Macular Oedema Screening — SCE Neurology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateMultiple Sclerosis & CNS InflammationFingolimod – Macular Oedema ScreeningSCE Neurology

A 45-year-old with relapsing-remitting multiple sclerosis is about to start fingolimod. She has type 2 diabetes but no visual symptoms. Which ophthalmic safety plan is most appropriate?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Arrange baseline assessment and repeat ophthalmic review at approximately three to four months for macular oedema

Fingolimod can cause macular oedema, most often in the first three to four months; diabetes and prior uveitis increase risk. Product information recommends ophthalmic assessment around three to four months after treatment initiation, with assessment before initiation as appropriate. Glaucoma, cataract and retinal detachment are not the characteristic fingolimod-specific complication.

Reference: Fingolimod Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/13873/smpc